Comera Life Sciences has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. If the Company is unable to complete a transaction, it may be required to seek a reorganization, liquidation or other restructuring. The Company does not expect to disclose or provide an update concerning developments related to this process unless or until the Company’s Board of Directors has approved a definitive course of action or otherwise determines that other disclosure is necessary or appropriate jurisdiction.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CMRA:
- Comera Life Sciences appoints Dorothy Clarke to board of directors
- Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
- Comera Life Sciences reports Q3 EPS (10c) vs (20c) last year
- Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
- Comera Life Sciences presents SQore platform technology data
